IMMUNIC, INC.
Close on Oct 19, 2026
- Market cap
- $297.17M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Immunic
Pharmaceutical Preparations, SIC 2834
Immunic, Inc. is a clinical-stage biotechnology company focused on developing oral therapies for serious chronic inflammatory and autoimmune conditions, specifically targeting neurologic and gastrointestinal diseases. The company’s pipeline includes vidofludimus calcium, a small molecule candidate currently in Phase 3 clinical trials for relapsing multiple sclerosis. Its gastrointestinal program, IMU-856, targets epithelial regeneration and intestinal barrier restoration for disorders such as celiac disease and inflammatory bowel disease. Additionally, Immunic is advancing the preclinical IMU-381 program, which utilizes its Nurr1 platform for autoimmune indications. Immunic does not have commercial products, focusing its activities on clinical-stage patient populations with significant unmet medical needs.
The company operates internationally, maintaining headquarters in New York City and directing primary research and clinical operations from Gräfelfing, Germany. Further research facilities are situated in Martinsried and Halle/Saale, Germany, along with a subsidiary conducting development activities in Melbourne, Australia. Immunic employed 92 people as of February 2026.
Summary of the business section of Immunic's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IMMUNIC, INC.
- Founded
- 2016
- Headquarters
- New York, X1
- Address
- 1200 Avenue Of The Americas, Suite 200 10036
- Phone
- (332) 255-9818
- Website
- imux.com
- Employees
- 92, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Minneapolis, MN
Stock & identifiers
- Ticker
- IMUX
- Exchange
- Nasdaq
- IPO date
- Apr 17, 2014
- Shares outstanding
- 14M, Jul 31, 2026
- Public float
- $83.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, May 13, 2026; 1-for-10 reverse, Apr 27, 2026; 1-for-50 reverse, Aug 8, 2019; 1-for-40 reverse, Apr 15, 2019
- SEC CIK
- 1280776
- CUSIP
- 4525EP200
- ISIN
- US4525EP2001
- LEI
- 549300R5T12FW5MEQB20
- EIN
- 56-2358443
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Duane Nash | Executive Chairman, Director | 45,256 |
| Jason Tardio | President and COO | 12,512 |
| Glenn Whaley | Chief Financial Officer | 95,510 |
| Erik Lundgren | Chief Executive Officer | – |
| Michael A. Panzara | Chief Medical Officer | – |
| Andreas Muehler | Chief Medical Officer | 582,466 |
| Value Trading Fund OS LP Biotechnology | Director | 427,629 |
| Partners L. P/Il Bvf | Director | – |
| Value Fund L. P. Biotechnology | Director | – |
| Partners OS Ltd. BVF | Director | – |
| Ii Gp Llc Bvf | Director | – |
| Robert Thorvald Nagel | Director | – |
| Value Fund Ii Lp Biotechnology | Director | – |
| I. Gp Llc Bvf | Director | – |
| Inc/Il Bvf | Director | – |
| Mark N. Lampert | Director | – |
| Gp Holdings Llc Bvf | Director | 42,762 |
| Elena Ridloff | Director | – |
| Jon Congleton | Director | – |
| Richard Alan Rudick | Director | 230,375 |
| Barclay A. Phillips | Director | – |
| Joerg Neermann | Director | 200,000 |
| Simona Skerjanec | Director | – |
| Michael W. Bonney | Director | – |
| Daniel Vitt | Director | 391,877 |
Employees
Headcount reported in annual reports
“As of February 1, 2026, we had 92 employees, nine of whom held M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 6, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 27, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 15, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 15, 2019 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 10, 2019 | Name change | Name changed from VITAL THERAPIES INC to IMMUNIC, INC. |
| Feb 4, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 26, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 17, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 15, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |